Sanjiv.Parant. Q3 FY26 Earnings Analysis

- The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions. - Pune plant to start contributing commercially from Q3 FY '26, with full-year revenue potential of INR 90-110 crores. - Optimal capacity utilization of the Pune plant expected by Q2 FY '27, potentially contributing INR 20-25 crores quarterly. - Base business growth projected at 15-20% for the next year (FY '27), with total revenue expected around INR 150 crores. - Alevia Healthcare joint venture is forecasted to contribute INR 1-1.5 crores to the bottom line in FY '26 and expected to grow at least 100% in FY '27 (INR 3-3.5 crores+). - The company aims to maintain flexibility with supply chain strategies to reduce timelines and respond to premium pricing opportunities. - Long-term growth targeted despite near-term regulatory and external market challenges, focusing on quality and diversified markets.

- The company expects a minimum of 10% sales growth for FY '26 compared to the previous year. - Alevia Healthcare (European nutraceutical venture) is projected to contribute around INR 1-1.5 crores to the bottom line in FY '26, with a potential 100% growth to INR 3-3.5 crores or more in FY '27. - The Pune IV plant venture is expected to generate INR 90-110 crores in a full year, with capacity utilization targeted by Q2 FY '27 and quarterly revenues of INR 20-25 crores from that point. - EBITDA margins and profitability may improve as new ventures ramp up and operational efficiencies increase through AI and modernization. - Earnings could benefit from reduced employee costs due to automation, and new government price revisions for IV products may be positive. - Overall, management is optimistic about sustainable and healthy growth across all business verticals in upcoming quarters.

- In H1 FY '26, Sanjivani Paranteral Limited undertook a capex of INR 1.04 crores. - The company is modernizing its facilities, incorporating AI to enhance efficiency and cost-effectiveness. - Development of import alternatives at the Pune plant is on track, with test licenses in place; products expected in the next 2-3 quarters. - The Pune plant has started commercial production recently and is expected to contribute INR 90-110 crores revenue on full-year operation, hitting optimal capacity by Q2 FY '27. - Future PPP (Public-Private Partnership) models are being explored; depending on investment size, funding may come from internal accruals, small loans, or external market fundraising. - Continuous upgradation in facilities, capex, and training is planned to meet tightening regulatory standards, especially for export markets.

- For future fundraising related to projects such as the PPP model for IV plants, the company will decide based on the capital required. - If the investment needed is around INR 10 crores, funding may be done through internal accruals or small loans. - For larger projects requiring INR 30-40 crores, the company may raise funds from the market (equity or debt). - No specific ongoing or planned equity fundraise was mentioned as of the November 2025 call. - The company is working on meeting parameters for NSE listing, but it will take 2-3 more quarters, indicating no immediate equity raising via public markets currently. - Overall, fundraising approach is opportunity-driven, with preference for internal accruals or loans for smaller needs and market raising for bigger investments.

- The Pune plant has a "very good healthy order book" in place, with commercial production started and business commencing from Q3 FY '26. - Orders for the Pune plant come from semi-government, government institutions, and exports to 3-4 established geographies. - Specific quantities of the Pune plant’s order book were not disclosed, with quantification to be provided later. - Orders worth approximately INR 1 crore were held back due to local unrest in Nepal but have since been dispatched. - Order books are reported to be good, supporting improved sales in the next two quarters. - There is a backlog of held shipments due to regulatory scrutiny, now being cleared and shipped, contributing to a positive outlook for Q3 and Q4. - The company is working on multiple opportunities, including government PPP ventures and international markets registrations, which may add orders soon.